Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
Top Cited Papers
Open Access
- 18 October 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (10) , e0002283
Abstract
Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of resistance on treatment outcomes. Mycobacterium tuberculosis (MTB) phenotypic drug susceptibility and whole-genome sequence (WGS) data, as well as patient profiles from 4 pretomanid-containing trials–STAND, Nix-TB, ZeNix and SimpliciTB–were used to investigate the rates of baseline resistance (BR) and acquired resistance (AR) to BPaL drugs, as well as their genetic basis, risk factors and impact on treatment outcomes. Data from >1,000 TB patients enrolled from 2015 to 2020 in 12 countries was assessed. We identified 2 (0.3%) participants with linezolid BR. Pretomanid BR was also rare, with similar rates across TB drug resistance types (0–2.1%). In contrast, bedaquiline BR was more prevalent among participants with highly resistant TB or longer prior treatment histories than those with newly diagnosed disease (5.2–6.3% vs. 0–0.3%). Bedaquiline BR was a risk factor for bacteriological failure or relapse in Nix-TB/ZeNix; 3/12 (25%, 95% CI 5–57%) participants with vs. 6/185 (3.2%, 1.2–6.9%) without bedaquiline BR. Across trials, we observed no linezolid AR, and only 3 cases of bedaquiline AR, including 2 participants with poor adherence. Overall, pretomanid AR was also rare, except in ZeNix patients with bedaquiline BR. WGS analyses revealed novel mutations in canonical resistant genes and, in 7 MTB isolates, the genetic determinants could not be identified. The overall low rates of BR to linezolid and pretomanid, and to a lesser extent to bedaquiline, observed in the pretomanid trials are in support of the worldwide implementation of BPaL-based regimens. Similarly, the overall low AR rates observed suggest BPaL drugs are better protected in the regimens trialed here than in other regimens combining bedaquiline with more, but less effective drugs.Keywords
Funding Information
- Department of Foreign Affairs and Trade, Australian Government
- Bill and Melinda Gates Foundation
- KfW Entwicklungsbank
- Irish Aid
- Netherlands Ministry of Foreign Affairs
- United States Agency for International Development
This publication has 41 references indexed in Scilit:
- Unexpected high prevalence of resistance-associatedRv0678variants in MDR-TB patients without documented prior use of clofazimine or bedaquilineJournal of Antimicrobial Chemotherapy, 2016
- Delamanid susceptibility testing ofMycobacterium tuberculosisusing the resazurin microtitre assay and the BACTEC™ MGIT™ 960 systemJournal of Antimicrobial Chemotherapy, 2016
- Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis2015
- Acquired Resistance of Mycobacterium tuberculosis to BedaquilinePLOS ONE, 2014
- Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux systemTuberculosis, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human MitochondriaMolecular Cell, 2007
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2002
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000